Zimmer Biomet Holdings, Inc. (NYSE:ZBH – Get Rating) has been given an average recommendation of “Hold” by the twenty-seven research firms that are currently covering the firm, Marketbeat.com reports. Two research analysts have rated the stock with a sell rating, thirteen have given a hold rating and eight have given a buy rating to the company. The average 12 month price objective among analysts that have covered the stock in the last year is $139.90.
Several equities research analysts have commented on ZBH shares. The Goldman Sachs Group dropped their target price on Zimmer Biomet from $179.00 to $155.00 and set a “buy” rating on the stock in a report on Monday, March 21st. Stifel Nicolaus upped their price target on Zimmer Biomet from $130.00 to $140.00 in a report on Tuesday, May 3rd. Truist Financial lowered their price target on Zimmer Biomet from $142.00 to $131.00 in a report on Wednesday, May 4th. Loop Capital downgraded Zimmer Biomet from a “buy” rating to a “hold” rating and set a $130.00 price target on the stock. in a report on Wednesday, March 2nd. Finally, Citigroup lowered their price target on Zimmer Biomet from $135.00 to $125.00 and set a “na” rating on the stock in a report on Tuesday, May 17th.
A number of institutional investors and hedge funds have recently modified their holdings of the business. Gilman Hill Asset Management LLC increased its position in Zimmer Biomet by 0.9% in the first quarter. Gilman Hill Asset Management LLC now owns 8,996 shares of the medical equipment provider’s stock worth $1,151,000 after buying an additional 81 shares in the last quarter. Donaldson Capital Management LLC increased its position in Zimmer Biomet by 5.2% in the fourth quarter. Donaldson Capital Management LLC now owns 1,655 shares of the medical equipment provider’s stock worth $210,000 after buying an additional 82 shares in the last quarter. SYM FINANCIAL Corp increased its position in Zimmer Biomet by 4.9% in the first quarter. SYM FINANCIAL Corp now owns 1,769 shares of the medical equipment provider’s stock worth $226,000 after buying an additional 82 shares in the last quarter. Roberts Glore & Co. Inc. IL increased its position in Zimmer Biomet by 1.0% in the first quarter. Roberts Glore & Co. Inc. IL now owns 8,323 shares of the medical equipment provider’s stock worth $1,065,000 after buying an additional 85 shares in the last quarter. Finally, YorkBridge Wealth Partners LLC grew its position in shares of Zimmer Biomet by 5.7% during the first quarter. YorkBridge Wealth Partners LLC now owns 1,837 shares of the medical equipment provider’s stock worth $235,000 after purchasing an additional 99 shares in the last quarter. Institutional investors and hedge funds own 90.34% of the company’s stock.
Zimmer Biomet (NYSE:ZBH – Get Rating) last released its earnings results on Tuesday, May 3rd. The medical equipment provider reported $1.61 EPS for the quarter, topping the consensus estimate of $1.40 by $0.21. Zimmer Biomet had a return on equity of 12.23% and a net margin of 2.85%. The business had revenue of $1.66 billion for the quarter, compared to the consensus estimate of $1.59 billion. During the same period in the previous year, the company posted $1.71 earnings per share. The company’s revenue for the quarter was up 3.9% compared to the same quarter last year. On average, equities research analysts predict that Zimmer Biomet will post 6.72 EPS for the current year.
The business also recently declared a quarterly dividend, which will be paid on Friday, July 29th. Shareholders of record on Monday, June 27th will be given a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a yield of 0.91%. The ex-dividend date is Friday, June 24th. Zimmer Biomet’s payout ratio is 93.20%.
About Zimmer Biomet (Get Rating)
Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates in the musculoskeletal healthcare business in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company designs, manufactures, and markets orthopaedic reconstructive products, such as knee and hip products; S.E.T.
- Get a free copy of the StockNews.com research report on Zimmer Biomet (ZBH)
- Victoria’s Secret Stock is Out of the Box
- Downturn Gives These 3 Buys Juicy Dividend Yields
- Time For a Ride in Six Flags Stock
- Why Dollar General (NYSE: DG) Should Be In Your Portfolio
- Korn Ferry Is A Good Buy For The Recession And Beyond
Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.